<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146873</url>
  </required_header>
  <id_info>
    <org_study_id>AAAE1145</org_study_id>
    <secondary_id>R01HD061255</secondary_id>
    <nct_id>NCT01146873</nct_id>
  </id_info>
  <brief_title>Treatment Options for Protease Inhibitor-exposed Children</brief_title>
  <acronym>NEVEREST-III</acronym>
  <official_title>Treatment Options for Protease Inhibitor-exposed Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that switching to a regimen based on efavirenz will be as
      effective and safe as remaining on a regimen based on Lopinavir/ritonavir for HIV-infected
      children.

      The investigators propose an unblinded randomized clinical trial to evaluate a
      simplification, protease-inhibitor (PI)-sparing treatment strategy among nevirapine
      (NVP)-exposed HIV-infected children treated initially with lopinavir/ritonavir (LPV/r).
      HIV-infected children aged 3-5 years, who have a history of exposure to NVP as part of
      prevention of mother-to-child HIV transmission (PMTCT), initiated LPV/r-based therapy in the
      first 36 months of life or who were enrolled on the control arm of Neverest 2 and who are
      virally suppressed with a viral load &lt; 50 copies/ml will be included. These children will be
      randomized to either substitute efavirenz (EFV) for LPV/r or to continue on their LPV/r-based
      regimen. Eight weeks prior to the primary randomization, eligible children will also be
      randomized to either remain on stavudine (D4T) or switch to abacavir (ABC). Children will be
      followed with regular viral load and other clinical tests for 48 weeks after the primary
      randomization. Children in the experimental arm who have breakthrough viremia (-defined as
      two subsequent viral loads &gt; 1000 copies/ml) on the EFV-based regimen will reinitiate the
      LPV/r regimen. The primary objective is to test whether the durability of viral suppression
      is equivalent when children are switched to EFV-based therapy. The primary study endpoint is
      failure to have HIV RNA &lt; 50 copies/ml and/or confirmed viremia &gt;1000 copies/ml. Secondary
      aims include comparison of immune preservation, toxicities, selection of resistance
      mutations, and adherence across the two arms. Antiretroviral drug concentrations and
      adherence will be investigated as possible explanations for the success and/or failure of
      this simplification regimen. The overall goal of the study is to contribute to the evidence
      base to allow expansion of treatment options for HIV-infected children in low resource
      settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Rebound</measure>
    <time_frame>48 weeks</time_frame>
    <description>Probability of viral rebound defined as &gt;=1 HIV RNA measurements &gt;50 copies/ml using survival analysis by 48 weeks post-randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>Probability of viral failure defined as &gt;= 2 HIV RNA measurements &gt;1000 copies/ml using survival analysis by 48 weeks post-randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 Cell Percentage at 48 Weeks After Randomization</measure>
    <time_frame>48 weeks</time_frame>
    <description>CD4 Cell Percentage at 48 Weeks After Randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization</measure>
    <time_frame>40 weeks</time_frame>
    <description>Percentage of participants with elevated total cholesterol, elevated LDL, abnormal HDL, or abnormal triglycerides at 40 weeks after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Grade ALT After Randomization</measure>
    <time_frame>through 48 weeks post randomization</time_frame>
    <description>Highest grade ALT after randomization. Grading was determined based on the Division of AIDS (2004) Toxicity Tables to grade adverse reactions. Grading scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (potentially life-threatening).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1: Lopinavir/ritonavir (LPV/r)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Efavirenz (EFV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Stavudine (D4T)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A: Abacavir (ABC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz (EFV)</intervention_name>
    <description>Children are assigned to begin a EFV-based antiretroviral based regimen.</description>
    <arm_group_label>Group 2: Efavirenz (EFV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir (LPV/r)</intervention_name>
    <description>Children are assigned to stay on their current LPV/r-based antiretroviral regimen.</description>
    <arm_group_label>Group 1: Lopinavir/ritonavir (LPV/r)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine (D4T)</intervention_name>
    <description>Children are assigned to stay on their current antiretroviral regimen which includes D4T.</description>
    <arm_group_label>Group D: Stavudine (D4T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir (ABC)</intervention_name>
    <description>Children stop taking D4T and switch to ABC.</description>
    <arm_group_label>Group A: Abacavir (ABC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled
             from outside or any age if enrolled from control arm of Neverest II.

          -  Reliable history or documented exposure to NVP used as part of PMTCT

          -  Initiated antiretroviral therapy with LPV/r at age less than 36 months

          -  Receiving LPV/r-based ART for at least 12 months

          -  At least one viral load measurement less than 50 copies/ml conducted as part of
             screening for the study

          -  ALT measurement grade I or less (DAIDS Toxicity Tables 2004) (Appendix A). These may
             be repeated until ALTs normalize if necessary.

        Exclusion criteria:

          -  Prior treatment with any NNRTI drug as part of a therapeutic regimen

          -  Substitution of other NRTI drugs (instead of 3TC and D4T which are the standard first
             line regimen) will be allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise Kuhn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rahima Moosa Mother and Child Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <results_reference>
    <citation>Coovadia A, Abrams EJ, Strehlau R, Shiau S, Pinillos F, Martens L, Patel F, Hunt G, Tsai WY, Kuhn L. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. JAMA. 2015 Nov 3;314(17):1808-17. doi: 10.1001/jama.2015.13631.</citation>
    <PMID>26529159</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <results_first_submitted>February 29, 2016</results_first_submitted>
  <results_first_submitted_qc>March 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2016</results_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Louise Kuhn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 300 study participants were recruited between June 2010 and October 2012.</recruitment_details>
      <pre_assignment_details>Two children discontinued the study prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Lopinavir/Ritonavir (LPV/r)</title>
          <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Efavirenz (EFV)</title>
          <description>Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Transfer out</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Lopinavir/Ritonavir (LPV/r)</title>
          <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Efavirenz (EFV)</title>
          <description>Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="298"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.26" spread="1.0"/>
                    <measurement group_id="B2" value="4.28" spread="0.9"/>
                    <measurement group_id="B3" value="4.27" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Viral Rebound</title>
        <description>Probability of viral rebound defined as &gt;=1 HIV RNA measurements &gt;50 copies/ml using survival analysis by 48 weeks post-randomization.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Lopinavir/Ritonavir (LPV/r)</title>
            <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Efavirenz (EFV)</title>
            <description>Participants are assigned to switch to an EFV-based antiretroviral regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Rebound</title>
          <description>Probability of viral rebound defined as &gt;=1 HIV RNA measurements &gt;50 copies/ml using survival analysis by 48 weeks post-randomization.</description>
          <units>probability of viral rebound</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.284" lower_limit="0.211" upper_limit="0.357"/>
                    <measurement group_id="O2" value="0.176" lower_limit="0.115" upper_limit="0.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that efavirenz is inferior to ritonavir-boosted lopinavir.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Kaplan-Meier methods</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.107</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Failure</title>
        <description>Probability of viral failure defined as &gt;= 2 HIV RNA measurements &gt;1000 copies/ml using survival analysis by 48 weeks post-randomization.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Lopinavir/Ritonavir (LPV/r)</title>
            <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Efavirenz (EFV)</title>
            <description>Participants are assigned to switch to an EFV-based antiretroviral regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Failure</title>
          <description>Probability of viral failure defined as &gt;= 2 HIV RNA measurements &gt;1000 copies/ml using survival analysis by 48 weeks post-randomization.</description>
          <units>probability of viral failure</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" lower_limit="0.002" upper_limit="0.043"/>
                    <measurement group_id="O2" value="0.027" lower_limit="0.001" upper_limit="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that efavirenz is inferior to ritonavir-boosted lopinavir.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Kaplan-Meier methods</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.007</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Cell Percentage at 48 Weeks After Randomization</title>
        <description>CD4 Cell Percentage at 48 Weeks After Randomization</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Lopinavir/Ritonavir (LPV/r)</title>
            <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Efavirenz (EFV)</title>
            <description>Participants are assigned to switch to an EFV-based antiretroviral regimen</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Percentage at 48 Weeks After Randomization</title>
          <description>CD4 Cell Percentage at 48 Weeks After Randomization</description>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="33.6" upper_limit="35.8"/>
                    <measurement group_id="O2" value="37.5" lower_limit="36.3" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization</title>
        <description>Percentage of participants with elevated total cholesterol, elevated LDL, abnormal HDL, or abnormal triglycerides at 40 weeks after randomization</description>
        <time_frame>40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Lopinavir/Ritonavir (LPV/r)</title>
            <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Efavirenz (EFV)</title>
            <description>Participants are assigned to switch to an EFV-based antiretroviral regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization</title>
          <description>Percentage of participants with elevated total cholesterol, elevated LDL, abnormal HDL, or abnormal triglycerides at 40 weeks after randomization</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Elevated total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Grade ALT After Randomization</title>
        <description>Highest grade ALT after randomization. Grading was determined based on the Division of AIDS (2004) Toxicity Tables to grade adverse reactions. Grading scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (potentially life-threatening).</description>
        <time_frame>through 48 weeks post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Lopinavir/Ritonavir (LPV/r)</title>
            <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Efavirenz (EFV)</title>
            <description>Participants are assigned to switch to an EFV-based antiretroviral regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Grade ALT After Randomization</title>
          <description>Highest grade ALT after randomization. Grading was determined based on the Division of AIDS (2004) Toxicity Tables to grade adverse reactions. Grading scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (potentially life-threatening).</description>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 48 weeks after randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Lopinavir/Ritonavir (LPV/r)</title>
          <description>Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Efavirenz (EFV)</title>
          <description>Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Seizures resolved after efavirenz was stopped and ritonavir-boosted lopinavir was restarted.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Louise Kuhn, PhD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-2398</phone>
      <email>lk24@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

